Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Pierre Fabre
Sort By
Newest First
1 / 1
1 / 1
Positive Opinion
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in adult patients with advanced BRAF-mutant melanoma
Pierre Fabre
PR-M08-18-NI-008
Aug 02, 2018
Clinical Data
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting
Pierre Fabre
PR-M05-18-NI-076
May 21, 2018
Launch
BMG Pharma S.r.l Announces the Launch of Its AFTACURE Gel and AFTACURE Spray
Pierre Fabre
PR-M03-18-NI-010
Mar 02, 2018
Clinical Trials
Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma
Array BioPharma
PR-M02-18-NI-043
Feb 13, 2018
Oncology
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival
Array BioPharma Inc.
PR-M01-18-NI-081
Jan 25, 2018
